NCT01355289View on ClinicalTrials.gov

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

May 31, 2014

Conditions
Thrombocytopenia
Interventions
DRUG

Avatrombopag

DRUG

Placebo

DRUG

Pegylated interferon (PEG-IFN)

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.

DRUG

Telaprevir

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

DRUG

Ribavirin

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

Trial Locations (2)

22031

Metropolitan Research, Fairfax

Unknown

Health Care Consultants, Los Angeles

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT01355289 - Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501 | Biotech Hunter | Biotech Hunter